[1]
|
Lundberg, I.E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., et al. (2021) Idiopathic Inflammatory Myopathies. Nature Reviews Disease Primers, 7, Article No. 86. https://doi.org/10.1038/s41572-021-00321-x
|
[2]
|
Mariampillai, K., Granger, B., Amelin, D., Guiguet, M., Hachulla, E., Maurier, F., et al. (2018) Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology, 75, 1528-1537. https://doi.org/10.1001/jamaneurol.2018.2598
|
[3]
|
Salzer, H.J.F., Schäfer, G., Hoenigl, M., Günther, G., Hoffmann, C., Kalsdorf, B., et al. (2018) Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia. Respiration, 96, 52-65. https://doi.org/10.1159/000487713
|
[4]
|
Bienvenu, A., Traore, K., Plekhanova, I., Bouchrik, M., Bossard, C. and Picot, S. (2016) Pneumocystis Pneumonia Suspected Cases in 604 Non-HIV and HIV Patients. International Journal of Infectious Diseases, 46, 11-17. https://doi.org/10.1016/j.ijid.2016.03.018
|
[5]
|
Chen, X., Shu, X., He, L., Yang, H., Lu, X., Wang, G., et al. (2023) High Prevalence and Mortality of Pneumocystis jirovecii Pneumonia in Anti-Mda5 Antibody-Positive Dermatomyositis. Rheumatology, 62, 3302-3309. https://doi.org/10.1093/rheumatology/kead063
|
[6]
|
Thompson, C., Piguet, V. and Choy, E. (2017) The Pathogenesis of Dermatomyositis. British Journal of Dermatology, 179, 1256-1262. https://doi.org/10.1111/bjd.15607
|
[7]
|
郝伟丽, 周晓鸿. 免疫因素在特发性炎症性肌病中的作用机制[J]. 皮肤病与性病, 2010, 32(2): 17-19.
|
[8]
|
Tournadre, A. and Miossec, P. (2009) Chemokines and Dendritic Cells in Inflammatory Myopathies. Annals of the Rheumatic Diseases, 68, 300-304. https://doi.org/10.1136/ard.2008.095984
|
[9]
|
Shamim, E.A., Rider, L.G., Pandey, J.P., O’Hanlon, T.P., Jara, L.J., Samayoa, E.A., et al. (2002) Differences in Idiopathic Inflammatory Myopathy Phenotypes and Genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic Influences in the Genetics and Clinical Expression of Myositis. Arthritis & Rheumatism, 46, 1885-1893. https://doi.org/10.1002/art.10358
|
[10]
|
Apostolopoulou, A. and Fishman, J.A. (2022) The Pathogenesis and Diagnosis of Pneumocystis Jiroveci Pneumonia. Journal of Fungi, 8, Article 1167. https://doi.org/10.3390/jof8111167
|
[11]
|
Harris, J.R., Balajee, S.A. and Park, B.J. (2010) Pneumocystis jirovecii Pneumonia: Current Knowledge and Outstanding Public Health Issues. Current Fungal Infection Reports, 4, 229-237. https://doi.org/10.1007/s12281-010-0029-3
|
[12]
|
Groll, A.H., Ritter, J. and Müller, F.C. (2001) Empfehlungen zur Prävention der Pneumocystis-carinii-Pneumonie bei Kindern und Jugendlichen mit neoplastischen Erkrankungen. Klinische Pädiatrie, 213, A38-A49. https://doi.org/10.1055/s-2001-17501
|
[13]
|
O’Riordan, D.M., Standing, J.E. and Limper, A.H. (1995) Pneumocystis Carinii Glycoprotein A Binds Macrophage Mannose Receptors. Infection and Immunity, 63, 779-784. https://doi.org/10.1128/iai.63.3.779-784.1995
|
[14]
|
Ezekowitz, R.A.B., Williams, D.J., Koziel, H., Armstrong, M.Y.K., Warner, A., Richards, F.F., et al. (1991) Uptake of Pneumocystis Carinii Mediated by the Macrophage Mannose Receptor. Nature, 351, 155-158. https://doi.org/10.1038/351155a0
|
[15]
|
Steele, C., Marrero, L., Swain, S., Harmsen, A.G., Zheng, M., Brown, G.D., et al. (2003) Alveolar Macrophage-Mediated Killing of Pneumocystis carinii F. sp. Muris Involves Molecular Recognition by the Dectin-1 Β-Glucan Receptor. The Journal of Experimental Medicine, 198, 1677-1688. https://doi.org/10.1084/jem.20030932
|
[16]
|
Limper, A.H., Hoyte, J.S. and Standing, J.E. (1997) The Role of Alveolar Macrophages in Pneumocystis Carinii Degradation and Clearance from the Lung. Journal of Clinical Investigation, 99, 2110-2117. https://doi.org/10.1172/jci119384
|
[17]
|
Beck, J.M., Preston, A.M., Wagner, J.G., Wilcoxen, S.E., Hossler, P., Meshnick, S.R., et al. (1998) Interaction of Ratpneumocystis Cariniiand Rat Alveolar Epithelial Cells in Vitro. American Journal of Physiology-Lung Cellular and Molecular Physiology, 275, L118-L125. https://doi.org/10.1152/ajplung.1998.275.1.l118
|
[18]
|
Beck, J.M., Preston, A.M., Wilcoxen, S.E., Morris, S.B., White, E.S. and Paine, R. (2003) Pneumocystis Pneumonia Increases the Susceptibility of Mice to Sublethal Hyperoxia. Infection and Immunity, 71, 5970-5978. https://doi.org/10.1128/iai.71.10.5970-5978.2003
|
[19]
|
Limper, A.H., Offord, K.P., Smith, T.F. and Martin, W.J. (1989) Pneumocystis carinii Pneumonia: Differences in Lung Parasite Number and Inflammation in Patients with and without Aids. American Review of Respiratory Disease, 140, 1204-1209. https://doi.org/10.1164/ajrccm/140.5.1204
|
[20]
|
Khoo, T., Lilleker, J.B., Thong, B.Y., Leclair, V., Lamb, J.A. and Chinoy, H. (2023) Epidemiology of the Idiopathic Inflammatory Myopathies. Nature Reviews Rheumatology, 19, 695-712. https://doi.org/10.1038/s41584-023-01033-0
|
[21]
|
Roux, A., Canet, E., Valade, S., Gangneux-Robert, F., Hamane, S., Lafabrie, A., et al. (2014) Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, France. Emerging Infectious Diseases, 20, 1490-1497. https://doi.org/10.3201/eid2009.131668
|
[22]
|
Thomas, C.F. and Limper, A.H. (2004) Pneumocystis Pneumonia. New England Journal of Medicine, 350, 2487-2498. https://doi.org/10.1056/nejmra032588
|
[23]
|
Liu, Y., Wang, X., Xu, J., Yang, Q., Zhu, H. and Yang, J. (2023) Diagnostic Value of Metagenomic Next-Generation Sequencing of Lower Respiratory Tract Specimen for the Diagnosis of Suspected Pneumocystis jirovecii Pneumonia. Annals of Medicine, 55, Article 2232358. https://doi.org/10.1080/07853890.2023.2232358
|
[24]
|
Bateman, M., Oladele, R. and Kolls, J.K. (2020) Diagnosing Pneumocystis jirovecii Pneumonia: A Review of Current Methods and Novel Approaches. Medical Mycology, 58, 1015-1028. https://doi.org/10.1093/mmy/myaa024
|
[25]
|
Mehta, P., Aggarwal, R., Porter, J.C. and Gunawardena, H. (2022) Management of Interstitial Lung Disease (ILD) in Myositis Syndromes: A Practical Guide for Clinicians. Best Practice & Research Clinical Rheumatology, 36, Article 101769. https://doi.org/10.1016/j.berh.2022.101769
|
[26]
|
Szvalb, A.D., Malek, A.E., Jiang, Y., Bhatti, M.M., Wurster, S. and Kontoyiannis, D.P. (2020) Serum (1,3)-Beta-D-Glucan Has Suboptimal Performance for the Diagnosis of Pneumocystis jirovecii Pneumonia in Cancer Patients and Correlates Poorly with Respiratory Burden as Measured by Quantitative PCR. Journal of Infection, 81, 443-451. https://doi.org/10.1016/j.jinf.2020.07.003
|
[27]
|
Taniguchi, J., Nakashima, K., Matsui, H., Watari, T., Otsuki, A., Ito, H., et al. (2021) Low Cut-Off Value of Serum (1,3)-Beta-D-Glucan for the Diagnosis of Pneumocystis Pneumonia in Non-HIV Patients: A Retrospective Cohort Study. BMC Infectious Diseases, 21, Article No. 1200. https://doi.org/10.1186/s12879-021-06895-x
|
[28]
|
Hammarström, H., Grankvist, A., Broman, I., Kondori, N., Wennerås, C., Gisslen, M., et al. (2019) Serum-Based Diagnosis of Pneumocystis Pneumonia by Detection of Pneumocystis jirovecii DNA and 1,3-Β-D-Glucan in HIV-Infected Patients: A Retrospective Case Control Study. BMC Infectious Diseases, 19, Article No. 658. https://doi.org/10.1186/s12879-019-4289-4
|
[29]
|
Liu, L., Yuan, M., Shi, Y. and Su, X. (2021) Clinical Performance of BAL Metagenomic Next-Generation Sequence and Serum (1,3)-Β-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Colonisation. Frontiers in Cellular and Infection Microbiology, 11, Article 784236. https://doi.org/10.3389/fc Pneumocystis jirovecii imb.2021.784236
|
[30]
|
Karageorgopoulos, D.E., Qu, J.-M., Korbila, I.P., Zhu, Y.-G., Vasileiou, V.A. and Falagas, M.E. (2013) Accuracy of Β-D-Glucan for the Diagnosis of Pneumocystis jirovecii Pneumonia: A Meta-Analysis. Clinical Microbiology and Infection, 19, 39-49. https://doi.org/10.1111/j.1469-0691.2011.03760.x
|
[31]
|
Lagrou, K., Chen, S., Masur, H., Viscoli, C., Decker, C.F., Pagano, L., et al. (2021) Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals without Human Immunodeficiency Virus. Clinical Infectious Diseases, 72, S114-S120. https://doi.org/10.1093/cid/ciaa1805
|
[32]
|
Tasaka, S. (2020) Recent Advances in the Diagnosis and Management of Pneumocystis Pneumonia. Tuberculosis and Respiratory Diseases, 83, Article 132. https://doi.org/10.4046/trd.2020.0015
|
[33]
|
Hsu, C., Ko, C., Wang, J., Hsu, T. and Lin, C. (2019) Comparing the Burdens of Opportunistic Infections among Patients with Systemic Rheumatic Diseases: A Nationally Representative Cohort Study. Arthritis Research & Therapy, 21, Article No. 211. https://doi.org/10.1186/s13075-019-1997-5
|
[34]
|
Sabbagh, S.E., Neely, J., Chow, A., DeGuzman, M., Lai, J., Lvovich, S., et al. (2020) Risk Factors Associated with Pneumocystis jirovecii Pneumonia in Juvenile Myositis in North America. Rheumatology, 60, 829-836. https://doi.org/10.1093/rheumatology/keaa436
|
[35]
|
Vassallo, R., Standing, J.E. and Limper, A.H. (2000) Isolated Pneumocystis Carinii Cell Wall Glucan Provokes Lower Respiratory Tract Inflammatory Responses. The Journal of Immunology, 164, 3755-3763. https://doi.org/10.4049/jimmunol.164.7.3755
|
[36]
|
Prévost, M. (1998) XV. Pneumocystosis Pathophysiology. FEMS Immunology and Medical Microbiology, 22, 123-128. https://doi.org/10.1016/s0928-8244(98)00069-8
|
[37]
|
Li, J., Wang, S., Zheng, J., Li, Q., Li, J. and Lu, L. (2022) Clinical Characteristics of and Risk Factors for Pneumocystis jirovecii Pneumonia in Anti-Melanoma Differentiation-Associated Gene 5 (Anti-Mda5) Antibody-Positive Dermatomyositis Patients: A Single-Center Retrospective Study. Clinical Rheumatology, 42, 453-462. https://doi.org/10.1007/s10067-022-06403-9
|
[38]
|
Mecoli, C.A. and Danoff, S.K. (2020) Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis. Current Rheumatology Reports, 22, Article No. 7. https://doi.org/10.1007/s11926-020-0883-0
|
[39]
|
Jin, F., Liu, X., Chen, W., Fan, Z. and Wang, H. (2019) High Initial (1, 3) Beta-D-Glucan Concentration May Be a Predictor of Satisfactory Response of C Aspofungin Combined with TMP/SMZ for HIV-Negative Patients with Moderate to Severe Pneumocystis jirovecii Pneumonia. International Journal of Infectious Diseases, 88, 141-148. https://doi.org/10.1016/j.ijid.2019.08.015
|
[40]
|
Quist, J. and Hill, A.R. (1995) Serum Lactate Dehydrogenase (LDH) in Pneumocystis Carinii Pneumonia, Tuberculosis, and Bacterial Pneumonia. Chest, 108, 415-418. https://doi.org/10.1378/chest.108.2.415
|
[41]
|
孟淑艳. 血清铁蛋白、CYFRA21-1及ESR在肺癌诊断和病情评估中的应用价值[J]. 中国卫生工程学, 2024, 23(4): 546-548.
|
[42]
|
刘昕, 张晓萌, 马楠, 等. 甲功、ESR、WBC、NLR在SAT急性炎症期和恢复期的比较分析[J]. 标记免疫分析与临床, 2022, 29(8): 1280-1284.
|
[43]
|
Kaplan, J.E., Benson, C., Holmes, K.K., Brooks, J.T., Pau, A., Masur, H. and HIV Medicine Association of the Infectious Diseases Society of America (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR Recommendations and Reports, 58, 1-207.
|
[44]
|
Maschmeyer, G., Helweg-Larsen, J., Pagano, L., Robin, C., Cordonnier, C. and Schellongowski, P. (2016) ECIL Guidelines for Treatment of Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Haematology Patients. Journal of Antimicrobial Chemotherapy, 71, 2405-2413. https://doi.org/10.1093/jac/dkw158
|
[45]
|
Park, J.W., Curtis, J.R., Kim, M.J., Lee, H., Song, Y.W. and Lee, E.B. (2019) Pneumocystis Pneumonia in Patients with Rheumatic Diseases Receiving Prolonged, Non-High-Dose Steroids—Clinical Implication of Primary Prophylaxis Using Trimethoprim-Sulfamethoxazole. Arthritis Research & Therapy, 21, Article No. 207. https://doi.org/10.1186/s13075-019-1996-6
|
[46]
|
Yale, S.H. and Limper, A.H. (1996) Pneumocystis Carinii Pneumonia in Patients without Acquired Immunodeficiency Syndrome: Associated Illnesses and Prior Corticosteroid Therapy. Mayo Clinic Proceedings, 71, 5-13. https://doi.org/10.4065/71.1.5
|
[47]
|
Winthrop, K.L. and Baddley, J.W. (2018) Pneumocystis and Glucocorticoid Use: To Prophylax or Not to Prophylax (and When). That Is the Question. Annals of the Rheumatic Diseases, 77, 631-633. https://doi.org/10.1136/annrheumdis-2017-212588
|
[48]
|
Sowden, E. and Carmichael, A.J. (2004) Autoimmune Inflammatory Disorders, Systemic Corticosteroids and Pneumocystis Pneumonia: A Strategy for Prevention. BMC Infectious Diseases, 4, Article No. 42. https://doi.org/10.1186/1471-2334-4-42
|